Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers

NCT02526017 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
313
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Five Prime Therapeutics, Inc.

Collaborators